NASDAQ:IPHA Innate Pharma Q4 2025 Earnings Report $1.76 -0.04 (-2.22%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.77 +0.01 (+0.62%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innate Pharma EPS ResultsActual EPS-$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInnate Pharma Revenue ResultsActual Revenue$2.41 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInnate Pharma Announcement DetailsQuarterQ4 2025Date2/14/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Innate Pharma Earnings HeadlinesInnate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?September 23 at 1:05 AM | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)September 22 at 8:25 AM | theglobeandmail.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. | Paradigm Press (Ad)Innate Pharma (NASDAQ:IPHA) Earns "Buy" Rating from BTIG ResearchSeptember 19, 2026 | americanbankingnews.comInnate Pharma S.A. (IPHA) Q2 2026 Earnings Call TranscriptSeptember 17, 2026 | seekingalpha.comInnate Pharma Reports H1 Loss Narrows; Advances Lacutamab And IPH4502September 17, 2026 | rttnews.comSee More Innate Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email. Email Address About Innate PharmaInnate Pharma (NASDAQ:IPHA) S.A. is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells. Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies. The company has also developed or advanced additional immuno-oncology programs involving natural killer-cell activation, immune checkpoints and antibody-drug conjugates. Its research and development activities are conducted through internal programs and collaborations with larger pharmaceutical companies. Innate Pharma operates internationally, with research, clinical development and collaboration activities spanning Europe, North America and other global markets. The company’s American Depositary Shares trade on the Nasdaq Global Select Market under the symbol IPHA, while its ordinary shares are listed in France. Innate Pharma is led by Chief Executive Officer Mondher Mahjoubi.View Innate Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
